Sexually Transmitted Diseases

The risk comes after it was found that surgical instruments used for orthopedic and spine surgeries were not cleaned properly and consequently, the sterilization of those instruments was compromised.

Novel HIV drug doravirine shows good potential in a recent clinical trial comparing it with established therapy darunavir.

The first case of gonorrhea resistant to available first-line antibiotics has been reported in the United Kingdom.

Dr. Tomlinson previously served as the principal deputy director for the DGHT and became the Acting Director in October 2017.

On the heels of revealing a new feature promoting HIV testing, a data analysis finds that the app was sharing sensitive information with other companies.

Only about 1 in 7 HIV-positive individuals are aware of their status.

While a new study has found that the HPV vaccination rate has more than tripled among young men in the United States, rates for both males and females are still well below public health targets.

Joseph Eron, MD, explains how some individuals acquire resistance to HIV therapy and discusses new drugs in the pipeline that are effective against resistant virus.

A new study from Johns Hopkins School of Medicine highlights major racial & ethnic disparities in the diagnosis and treatment of trichomoniasis in the United States.

This comes on the heels of 2 recent FDA approvals of 2 Mylan antiretrovirals: Cimduo and Symfi Lo.

Colleen Kelley, MD, stresses the importance of routinizing HIV testing and shares what physicians can do if their patient declines the option to get tested.

A recent study finds that daily antituberculosis therapy is more effective than a thrice-weekly regimen among HIV-positive patients with pulmonary tuberculosis.

A new study finds that a 1-month course of antibiotics is as safe & effective as the commonly recommended 9-month course in preventing tuberculosis in those with HIV.

A new study suggests that an antiretroviral combination of dolutegravir with darunavir/cobicistat can be prescribed safely in the treatment of HIV-1.

AIDS researcher Robert Redfield, MD, has officially been named the new director of the CDC.

Joseph Eron, MD, discusses when clinicians may expect to have access to long-acting injectable ART and the different opportunities it offers for individuals with HIV.

Implementation of a rapid entry program decreased time to first provider appointment, time to initiation of ART, and time to viral suppression in the Southern United States.

Colleen Kelley, MD, explains what is needed to ensure that individuals get tested for HIV.

D/C/F/TAF achieved high virologic response rates that were overall noninferior to the control D/C+F/TDF, as well as favorable bone and renal outcomes that were consistent across age, gender, and race subgroups in phase 3 AMBER trial.

Posthoc analysis of the EMERALD trial reveal the combination regimen of D/C/F/TAF performs well in HIV-positive patients across different race, gender, and age subgroups, who may have failed previous antiviral regimens.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

All doses of MK-8591 were generally well-tolerated with a limited number of reported mild/moderate adverse events.

Recent research presented at CROI 2018 finds that the risk of female HIV acquisition per sex act steadily increased through pregnancy and was highest during postpartum.

Recent research presented at CROI reveals that doxycycline is an acceptable treatment alternative for HIV-positive patients who are infected with syphilis.

Researchers discuss a new method to rapidly detect HIV time-space clusters for public health intervention at CROI 2018.

At present, multiple vaccine candidates are in various stages of research and development, including cabotegravir, which is currently in phase 3 trials, and vaccines based on broadly-neutralizing antibodies.

A recent study has found that patients with HIV are six times more likely to have schizophrenia compared with those who do not have the virus.

At CROI 2018, Dr. Patricia Flynn discussed the impact of ART on individuals with perinatal HIV infections, and how far the infectious disease community has come since its initial use.

Raltegravir-intensified therapy resulted in significantly faster viral load declines in HIV-infected adults and older children but did not reduce overall mortality or WHO 3/4 events compared with standard triple-drug ART.

Mental health is a critical component of ending the HIV epidemic.